MACREGEN
MACREGEN
Industry:
Medical
Address:
Birmingham, Birmingham, United Kingdom
Country:
United Kingdom
Website Url:
http://www.macregen.net
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy DNS Google Google Cloud OpenResty
Current Employees Featured
Official Site Inspections
http://www.macregen.net
- Host name: a2aa9ff50de748dbe.awsglobalaccelerator.com
- IP address: 3.33.130.190
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "MacRegen"
MacRegen - Crunchbase Company Profile & Funding
MacRegen is located in Birmingham, Birmingham, United Kingdom. Who are MacRegen's competitors? Alternatives and possible competitors to MacRegen may include ClÃnicas …See details»
MacRegen - Company Profile - Tracxn
Nov 17, 2024 · MacRegen - Developer of therapeutic solutions for treating multiple retinal disorders. This company is not active anymore. Founded by B Michael Silber in the year 2018.See details»
MacRegen Company Profile | Management and Employees List
MacRegen Inc. is a pre-clinical stage biotechnology company seeking to develop, register, and commercialize first-in-class breakthrough drugs. We provide drugs for the treatment of both …See details»
Researchers are one step closer to developing eye drops to treat …
Jul 19, 2018 · The scientists’ pending patents for the eye drops are now owned by US-based company Macregen Inc, and a team of Birmingham researchers is working with the company …See details»
Researchers are one step closer to developing eye drops to treat …
Jul 19, 2018 · The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company …See details»
Macregen - Products, Competitors, Financials, Employees, …
Macregen provides customized equipment solutions tailored to the specific needs of their clients, leveraging patented technologies to ensure high-quality powder processing. It is based in San …See details»
An eye drop for macular degeneration shows promise in animal …
Jul 19, 2018 · The eye drop contains a peptide that can penetrate cells in the retina. It is now being developed by a startup in the U.S. called Macregen, according to a statement.See details»
Jake Requard - Manager, Business Development and Investor
· Experience: MacRegen, Inc. · Education: Loyola College in Maryland · Location: Apex · 500+ connections on LinkedIn. View Jake Requard’s profile on LinkedIn, a professional community …See details»
MacRegen - Contacts, Employees, Board Members, Advisors
MacRegen has 1 current employee profile, President and Chief Executive Officer Michael Silber. MacRegen provides drugs for the treatment of both dry and wet AMD.See details»
Macregen - Overview, News & Competitors | ZoomInfo.com
Macregen, Inc. is dedicated to the development of transformative therapies for the preservation of eye sight and treatment for people suffering from age-related macular degeneration (AMD) …See details»
Researchers are one step closer to developing | EurekAlert!
Jul 19, 2018 · Macregen, Inc. is dedicated to the development of transformative therapies for the preservation of eye sight and treatment for people suffering from age-related macular …See details»
MacRegen - Tech Stack, Apps, Patents & Trademarks - Crunchbase
MacRegen is actively using 17 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and SPF. MacRegen provides drugs for the …See details»
MITIA - MacRegen, Inc. Trademark Registration - US Patent and …
Website: macregen.net: Research: OneLook Acronym Finder; Serial Number: 90448322: Mark Literal Elements: MITIA: Mark Drawing Type: 4 - STANDARD CHARACTER MARK: Mark ...See details»
Patents Assigned to MacRegen, Inc. - Justia Patents Search
Dec 21, 2020 · Abstract: The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders.See details»
Researchers Planning Human Trials for Anti-VEGF Eye Drops - HCP …
Dec 17, 2018 · The researchers say that following successful trials on rabbit and pig eyes, they are ready to move forward with trials on human eyes in 2019. The research team also says it …See details»
Introduction to Macregen, Age-Related Macular Degeneration
Introduction to Macregen, Age-Related Macular Degeneration, and Mitia (TM) by B. Michael Silber PhD. Macregen's President and Chief Executive Officer.See details»
Michael Silber - President and Chief Executive Officer
Michael Silber has 3 current jobs including President and Chief Executive Officer at MacRegen, President and Chief Executive Officer at Reiley Pharmaceuticals, and Adjunct Professor, …See details»
Keith Roizman, Executive Chairman and CTO Discusses the …
Keith Roizman, Macregen Inc. Executive Chairman and Chief Technology Officer discusses the OPHTHAMIZEâ„¢ Program for treating AMD and other diseases.See details»
macrogen
Macrogen, a global leader in digital healthcare powered by Big Data and AI, is dedicated to delivering a $100 'DNA blueprint' to advance precision medicine.See details»
Macrogen - Wikipedia
Macrogen operates worldwide through a network of branch offices and subsidiaries. In 2004, it founded Macrogen Corp. in the US, which in 2019 became Psomagen Inc. In 2008, it …See details»